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OBJECTIVE: We evaluated the incidence of and the main risk factors associated with cutaneous adverse events
in patients with chronic inflammatory arthritis following anti-TNF-a therapy.
METHODS: A total of 257 patients with active arthritis who were taking TNF-a blockers, including 158 patients
with rheumatoid arthritis, 87 with ankylosing spondylitis and 12 with psoriatic arthritis, were enrolled in a 5-
year prospective analysis. Patients with overlapping or other rheumatic diseases were excluded.
Anthropometric, socioeconomic, demographic and clinical data were evaluated, including the Disease
Activity Score-28, Bath Ankylosing Spondylitis Disease Activity Index and Psoriasis Area Severity Index. Skin
conditions were evaluated by two dermatology experts, and in doubtful cases, skin lesion biopsies were
performed. Associations between adverse cutaneous events and clinical, demographic and epidemiological
variables were determined using the chi-square test, and logistic regression analyses were performed to identify
risk factors. The significance level was set at p,0.05.
RESULTS: After 60 months of follow-up, 71 adverse events (73.85/1000 patient-years) were observed, of which
allergic and immune-mediated phenomena were the most frequent events, followed by infectious conditions
involving bacterial (47.1%), parasitic (23.5%), fungal (20.6%) and viral (8.8%) agents.
CONCLUSION: The skin is significantly affected by adverse reactions resulting from the use of TNF-a blockers,
and the main risk factors for cutaneous events were advanced age, female sex, a diagnosis of rheumatoid
arthritis, disease activity and the use of infliximab.
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& INTRODUCTION
A number of studies have demonstrated that TNF-a
blockers, including monoclonal antibodies (infliximab [IFX],
adalimumab [ADA] and golimumab [GOL]) and soluble
TNF receptors (etanercept [ETN]), are effective in the
treatment of rheumatoid arthritis (RA) (1), ankylosing
spondylitis (AS) (2), psoriatic arthritis (PA) (3), juvenile
idiopathic arthritis (JIA) (4), psoriasis (5) and inflammatory
bowel disease (6). However, these medications are
associated with the occurrence of skin manifestations
(dermatosis and dermatitis), with a frequency ranging from
10% to 60% (7-9).
Undesirable events generally quickly resolved after the
withdrawal of TNF-a blockers or with the use of glucocor-
ticoid steroids (GCs) (10,11) or antimicrobial agents. In some
cases, it is possible to maintain treatment or to switch to
another TNF-a blocker or biologic agent, such as rituximab
(RTX), abatacept (ABT) or tocilizumab (TCZ) (1).
Among the types of acute lesions, the main differential
diagnoses include allergic, urticariform and infectious
manifestations caused by viruses (especially herpes), bac-
teria (e.g., staphylococcus and streptococcus), fungi (can-
dida) and parasites (especially scabies) (7,8,12,13).
The majority of chronic lesions consist of psoriasis-like
eczema (13,14), although herpetiform dermatitis, small
vessel vasculitis, alopecia areata, palmoplantar pustulosis,
atopic dermatitis, lichenoid rash, purpura, skin neoplasms,
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polymorphic and multiform erythema have also been
reported (7,8,15).
The aim of the present study was to evaluate the
incidence and the main risk factors associated with
cutaneous adverse events (CAEs) in patients with chronic
inflammatory arthropathies (CIAs) who receive TNF-a
blockers.
& PATIENTS AND METHODS
A total of 257 patients with active CIA and who were
receiving TNF-a blockers were evaluated, including 158
(61.5%) patients with RA (ACR, 1987) (16), 87 (33.8%) with
AS (modified New York criteria, 1984) (17) and 12 (4.7%)
with PA (CASPAR, 2006) (18), in a prospective analysis
from January 2005 to December 2009. All of the patients
were regularly followed at the Immunobiological Clinic of
the Rheumatology Division of the Universidade Federal de
Sa˜o Paulo/Escola Paulista de Medicina (Brazil), and all of
the patients demonstrated moderate to severe disease
activity and had received anti-TNF-a therapy for the
previous 6 months (19,20). The patients were evaluated in
the same manner every 3 months, regardless of the type of
TNF-blocker administration (i.e., intravenous or subcuta-
neous).
The following exclusion criteria were applied: inability to
answer the questions on the questionnaires; active or
chronic active infections, including hepatitis B, hepatitis C
and human immunodeficiency virus; overlapping of other
autoimmune rheumatic diseases; pulse with methylpredni-
solone; recurrent infections involving the skin and/or
mucosal tissue, such as erysipelas, furunculosis, human
papillomavirus and herpes simplex; and classic contra-
indications for TNF-a inhibitors (solid and hematological
neoplasms, demyelinating disease and heart failure).
Anthropometric, socioeconomic, demographic and clin-
ical data were evaluated, including the Disease Activity
Score-28 (DAS28) (21), Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) (22), Psoriasis Area and Severity
Index (PASI) (23) and Health Assessment Questionnaire
(HAQ).
Comorbidities were grouped based on the International
Classification of Diseases (10th revision) (http://www.
icd10data.com), and concomitant medications were classi-
fied according to the Dictionary of Pharmaceutical
Specialties (version 2009, Brazil (http://www.epuc.com.
br/DEF/Home.htm). Certain drugs have been associated
with drug-induced skin conditions, and others have been
shown to increase the odds of infection. For this reason,
these drugs were analyzed separately, including analgesics,
non-steroidal anti-inflammatory drugs (NSAIDs), GCs,
disease-modifying anti-rheumatic drugs (DMARDs; includ-
ing methotrexate, leflunomide, cyclosporine, sulfasalazine,
and azathioprine), hypertension medications (methyldopa,
hydralazine, angiotensin-converting-enzyme inhibitors),
anticonvulsants and treatment for latent tuberculosis infec-
tion (isoniazid).
Skin conditions were evaluated by two experienced
dermatologists. In cases of doubt or a lack of agreement
between the examiners, a biopsy of the skin lesion was
performed following the standard routine procedures.
Staining with hematoxylin-eosin was used in all cases.
Special stains, direct immunofluorescence and cultures of
fragments were performed when necessary. An adverse
event was defined as any unexpected medical occurrence
that arose following the onset of anti-TNF-a therapy. A
serious adverse event was defined as any unexpected
medical occurrence that resulted in death, endangered the
patient’s life or required or prolonged hospitalization. These
events did not necessarily have a causal relationship with
the factors evaluated in the study.
Immunological reactions to the drugs were defined,
according to the classification proposed by Gell and
Coombs (1963), as type I (allergy or anaphylaxis, such as
urticariform reaction), type II (antibody-mediated cytotoxic
reaction, such as hemolytic anemia, thrombocytopenia and
nephritis), type III (immune complex-mediated reactions,
such as psoriasis-like lesions and drug-induced lupus) or
type IV (cell-mediated reaction, such as contact dermatitis)
hypersensitivity (24). Infectious events were classified as
viral, parasitic, fungal or bacterial, depending on the clinical
condition or on identification of the etiological agent
through direct study, culture or specific staining.
The incidence was calculated based on the time interval
between the first day of TNF-a blocker use and the first
CAE. Recurring conditions were not included in this
analysis. The decision to maintain or discontinue (tempora-
rily or definitively) the medication was made by the medical
team based on the risks, benefits, severity, duration,
likelihood and temporality between the CAEs and the
TNF-a inhibitors.
Descriptive data are expressed as the means ¡ standard
deviations, and categorical variables are expressed as
percentage values. For the inferential analysis, Student’s t-
test and the chi-square test were used for numerical data,
and the Mann-Whitney and Fisher’s exact test were used for
categorical variables. Analysis of variance and Tukey’s post-
hoc test were used for the comparison of non-numerical
data. All of the data were initially evaluated for distribution
normality. Associations between CAEs and the clinical,
demographic and epidemiological variables were evaluated
using the chi-square test and logistic regression models for
the identification of associated risk factors. The dependent
variables were the CAEs. The Statistical Package for Social
Sciences (SPSS, version 15.0) was used for all of the analyses,
with the level of significance set at 5% (p,0.05).
Ethics
All of the patients were informed about the study, and
those who agreed to participate signed a statement of
informed consent. This study received approval from the
Human Research Ethics Committee of the Universidade
Federal de Sa˜o Paulo/Escola Paulista de Medicina (no.
1478/09).
& RESULTS
After 60 months of follow-up, 71 (27.6%) patients
experienced some type of adverse event involving the skin
(Table 1). The incidence of CAE was 73.85/1000 patient-
years. No patient presented evidence of a similar pre-
existing clinical condition. The first CAE appeared between
2 weeks and 45 months after the onset of anti-TNF-a therapy
(mean: 11.2¡4.7 months). The diagnosis of skin lesions,
including lepromatous leprosy (LL), systemic lupus erythe-
matosus (SLE), psoriasis-like lesions and vulvar lichen
planus, was confirmed through biopsy of the affected area.
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Onychomycosis was proved according to the positivity of
the direct mycological test.
Table 2 displays the clinical characteristics of the 257
patients according to the presence of CAEs. Older indivi-
duals and those with a more elapsed time since their
diagnoses, those with greater disease activity and severity,
those of female sex, those with a history of diabetes mellitus,
those with a diagnosis of RA and those with regular use of
IFX demonstrated a greater likelihood of experiencing a
CAE.
Allergic and immune-mediated phenomena were the
most frequent types of CAEs (n= 37; 52.1%), followed by
infectious conditions (n = 34; 47.9%) involving bacterial
(47.1%), parasitic (23.5%), fungal (20.6%) and viral (8.8%)
agents (Figure 1; Table 3).
When the 71 patients with CAE were grouped according
to the mechanism involved (immune-allergic vs. infectious),
the only significant variable associated with the greater
frequency of the latter group was a diagnosis of diabetes
mellitus. In addition, there was a tendency toward
infectious CAEs occurring more frequently in patients
under prolonged treatment with GCs, regardless of the
dose (Table 4).
Although the severity of the events was considered
moderate to severe in most patients, the resolution of the
CAEs was satisfactory in the vast majority of cases following
withdrawal of the anti-TNF-a agent and with the use of
specific medications, such as anti-histamines, GCs, anti-
biotics and antiviral, antiparasitic and antimycotic agents,
depending on the event and needs of each case. Table 5
displays the strategies regarding the discontinuation (tem-
porary or definitive) of TNF-a blockers. Among those
patients for whom therapy was temporarily discontinued,
the same medication was reintroduced without recurrence
of the CAE. The replacement of anti-TNF-a agents was the
most frequent action undertaken following the definitive
discontinuation of the first blocker, with no recurrence of
the CAE during the first 6 months following replacement.
Among those who needed to switch medications to
another TNF-a inhibitor, the majority switched from
monoclonal antibody therapy to soluble receptor therapy
(53.8%), followed by from treatment with one monoclonal
antibody to another monoclonal antibody (33.1%) and from
treatment with a soluble receptor to a monoclonal antibody
(13.1%). Only four patients switched to a non-TNF-a
blocker, including three who used RTX and one who used
ABT.
Three CAE (4.22%) cases required hospitalization and
were therefore classified as serious. In all of the cases, the
Table 1 - The frequency of 71 new CAEs in 257 patients
with chronic inflammatory arthritis taking TNF-a blockers
after 60 months of follow-up.
Frequency, n (%)
Urticaria 18 (25.3%)
Local erythema 12 (16.9%)
Scabies 8 (11.3%)
Impetigo 6 (8.4%)
Onychomycosis 4 (5.6%)
Psoriasis-like lesions 3 (4.2%)
Chronic eczema 3 (4.2%)
Tina corporis/cruris 3 (4.2%)
Boils 2 (2.8%)
Recurrent furunculosis 2 (2.8%)
Erysipelas 2 (2.8%)
Soft tissue abscess 2 (2.8%)
Herpes simplex
Oral 1 (1.4%)
Genital 1 (1.4%)
Herpes zoster 1 (1.4%)
Lichen planus 1 (1.4%)
Lepromatous leprosy 1 (1.4%)
Systemic lupus erythematosus 1 (1.4%)
Table 2 - Clinical characteristics of the 257 patients with chronic inflammatory arthritis taking TNF-a blockers according
to the presence of CAEs.
Total (n = 257) No CAE (n=186) With CAE (n=71) p-value
Age (years) 47.5¡12.3 46.8¡11.6 50.3¡10.7 0.03
Years since diagnosis 13.6¡7.2 12.5¡7.8 15.8¡8 0.02
Female sex, n (%) 165(64.2%) 107(57.5%) 58(81.7%) ,0.001
DAS28 (n= 170) 5.92¡1.34 5.47¡1.13 5.88¡1.41 0.02
BASDAI (n= 91) 5.2¡1.9 4.9¡1.8 5.3¡2.0 0.03
PASI (n =12) 8.7¡4.2 7.3¡3.9 9.5¡4.6 0.04
HAQ 1.72¡0.61 1.63¡0.5 1.79¡0.6 0.04
Associated disease
DM, n (%) 64 (24.9%) 39 (21%) 25 (35.2%) 0.02
Concomitant medication
GCs, n (%) 151 (58.8%) 98 (52.7%) 53 (74.6%) 0.04
DMARDs, n (%) 238 (92.6%) 173 (93%) 65 (91.5%) 0.29
Antihypertensive, n (%) 96 (37.4%) 71 (38.2%) 25 (35.2%) 0.42
Anticonvulsant, n (%) 6 (2.3%) 4 (2.1%) 2 (2.8%) 0.78
Chronic inflammatory arthritis
RA, n (%) 158 (61.5%) 107 (57.5%) 51 (71.9%)
AS, n (%) 87 (33.8%) 72 (38.7%) 15 (21.1%)
PA. N (%) 12 (4.7%) 7 (3.8%) 5 (7%) ,0.001
TNF-a blockers
IFX, n (%) 132 (51.4%) 94 (50.5%) 38 (53.5%)
ADA, n (%) 75 (29.2%) 56 (30.1%) 19 (28.2%)
ETN, n (%) 50 (19.4%) 36 (19.3%) 14 (16.9%) ,0.001
CAEs: cutaneous adverse events; DAS28: Disease Activity Score-28; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; PASI: Psoriasis Activity and
Severity Index; HAQ: Health Assessment Questionnaire; DM: diabetes mellitus; GCs: glucocorticoid steroids; DMARDs: disease-modifying anti-rheumatic
drugs; RA: rheumatoid arthritis; AS: ankylosing spondylitis; PA: psoriatic arthritis; IFX: infliximab; ETN: etanercept; ADA: adalimumab.
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reason for hospitalization was an acute bacterial condition
(erysipelas, recurring furunculosis and soft tissue abscess),
with toxemia and/or evidence of septicemia and/or an
inadequate response to outpatient treatment. In addition,
there was a close temporal and causal relationship between
the study procedures or therapeutic agent employed and
the patient’s classification as moderately severe, based on
the investigator’s opinion. No cases resulted in death. These
serious adverse events exhibited satisfactory evolution
following antibiotic therapy, with complete resolution of
the disease process. In all three cases, the anti-TNF-a agent
was switched (to ETN in two of the cases and to RTX in the
other case). No statistically significant association was
found between serious adverse events and age, years since
diagnosis, functional capacity, concomitant medications or
associated diseases.
In the logistic regression model, the main risk factors
significantly associated with CAE were advanced age,
female sex, greater disease activity, diagnosis of RA and
the use of GCs and IFX. HAQ, DMARDs and other
concomitant medications, as well as the presence of diabetes
mellitus, did not achieve statistical significance as risk
Figure 1 - Grouping of CAEs according to mechanism involved (immune-allergic vs. infectious)
Table 3 - Clinical characteristics of the 71 CAEs according to the mechanism involved (immune-allergic vs. infectious).
Total (n = 71) Immune-allergic (n = 37) Infectious (n= 34)
Age (years) 50.3¡10.7 49.2¡10.9 50.6¡12.1 0.31
Years since diagnosis 15.8¡8 14.4¡7.4 15.8¡8.2 0.46
Female sex, n (%) 58(81.7%) 30(81.1%) 28(82.3%) 0.26
DAS28 (n = 170) 5.88¡1.41 5.81¡1.27 5.97¡1.35 0.51
BASDAI (n = 91) 5.3¡2 5.0¡1.7 5.4¡1.9 0.44
HAQ 1.79¡0.6 1.71¡0.6 1.82¡0.6 0.17
Associated disease, n (%)
DM, n (%) 25 (35.2%) 8 (21.6%) 17 (50%) 0.03
Concomitant medication
GCs, n (%) 53 (74.6%) 24 (64.9%) 29 (85.3%) 0.06
DMARDs, n (%) 65 (91.5%) 34 (91.9%) 31 (91.2%) 0.58
Antihypertensive, n (%) 25 (35.2%) 15 (40.5%) 10 (29.4%) 0.29
Anticonvulsant, n (%) 2 (2.8%) 2 (5.4%) 0 (0%) 0.32
Chronic inflammatory arthritis
RA, n (%) 51 (71.9%) 24 (64.9%) 27 (79.4%) 0.14
AS, n (%) 15 (21.1%) 9 (24.3%) 6 (17.6%) 0.25
PA, n (%) 5 (7%) 2 (5.4%) 3 (8.8%) 0.37
TNFa blockers
IFX, n (%) 38 (53.5%) 22 (59.5%) 16 (47.1%) 0.07
ADA, n (%) 19 (28.2%) 13 (35.1%) 8 (23.5%) 0.25
ETN, n (%) 14 (16.9%) 10 (27%) 4 (11.8%) 0.09
DAS28: Disease Activity Score-28; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; HAQ: Health Assessment Questionnaire; RA: rheumatoid
arthritis; AS: ankylosing spondylitis; PA: psoriatic arthritis; DM: diabetes mellitus; GCs: glucocorticoid steroids; DMARDs: disease-modifying anti-rheumatic
drugs; IFX: infliximab; ETN: etanercept; ADA: adalimumab.
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factors following multiple statistical adjustments. The time
since diagnosis exhibited multi-collinearity with age and
was therefore removed from the final model. No protection
factors were identified. The PASI did not remain in the
model following the statistical adjustments, whereas IFX
remained in the model even after controlling for frequency,
duration of use and exposure.
& DISCUSSION
TNF-a blockers are associated with a variety of potentially
serious adverse events, especially allergic/immune-
mediated phenomena and opportunistic infections or
infections caused by common germs involving the skin
and internal squamous mucosae.
Our findings demonstrate that CAEs are frequent in the
clinical practice of rheumatology, affecting approximately
25% of patients with CIA who use TNF-a blockers, with a
high incidence (73.85 in every 1,000 patient-years).
Moreover, advanced age, female sex, RA, disease activity
and current use of GCs and IFX were the main risk factors
significantly associated with CAEs. Thus, patient-related
aspects, the diagnosis and the TNF-a blocker itself play
relevant roles in the clinical condition and management of
affected individuals.
The pharmacological and biochemical properties of three
TNF-a blockers could explain the variations in the risk of
infection and other adverse reactions. Chimeric (IFX) and
human (ADA/GOL) monoclonal antibodies neutralize
soluble, membrane-bound TNF-a to a greater extent and
for a longer time, whereas ETN only binds to the soluble
fraction in an irreversible manner over a shorter time span.
In addition, IFX and ADA/GOL more strongly promote
apoptosis, along with significant dose-dependent reductions
in the level of interferon-gamma (IFN-c), whereas ETN does
not demonstrate these characteristics. Furthermore, this
reduced level of IFN-c could be associated with the failed
inhibition of pathogen growth, especially intracellular
pathogens (25).
Notably, the spectrum of infectious conditions is quite
variable, depending on the country of registry and the type
of TNF-a blocker used. The French registry (RATIO) found
that 33% of non-tuberculosis opportunistic infections among
users of TNF-a blockers were bacterial (listeriosis, nocar-
diosis, atypical mycobacteria, non-typhoid salmonellosis),
whereas 40% were viral (severe herpes zoster [shingles],
chicken pox, disseminated herpes simplex, disseminated
cytomegalovirus), 22% were fungal (pneumocystosis, inva-
sive aspergillosis, cryptococcosis), and 4% were parasitic
(leishmaniasis). Furthermore, nearly 25% of patients
required hospitalization in intensive care, and the mortality
rate was 10%. The main risk factors associated with these
infections were treatment with IFX (OR=17.6; 95% CI: 4.3 to
72.9; p,0.0001) or ADA (OR=10; 95% CI: 2.3 to 44.4;
p= 0.002) vs. ETN and previous use of GCs (OR=6.3; 95%
CI: 2 to 20; p= 0.002) (26). Lower hospitalization and
mortality rates were observed in the present study, which
was undertaken at a tertiary university hospital and which
involved patients with long-standing diagnoses and other
factors associated with a poorer prognosis; however, no
cases of non-tuberculosis opportunistic infection were
observed over the 5 years of follow-up.
According to a recent retrospective analysis (1998 to 2005)
involving more than 20,000 RA patients, including nearly
4,000 users of TNF-a blockers, the risk of hospitalization due
to infection, especially of the skin or airways, was greater
following the chronic use of GCs (hazard ratio [HR] = 2.14;
95% CI: 1.88 to 2.43), even after controlling for demographic
variables, comorbidities and traditional DMARDs. With
some TNF-a blockers, the risk was 24% greater (HR=1.24;
95% CI: 1.02 to 1.5), particularly when IFX was used
(HR=1.51; 95% CI: 1.14 to 2.0). In addition, the hospitaliza-
tion rate was 7%, mainly in the first 6 to 12 months of
treatment (27).
In the present study, the use of GCs was associated with a
greater chance of experiencing a CAE. Interestingly, the
greater risk of infection among RA patients has not achieved
statistical significance in randomized clinical trials, which
might reflect the heterogeneity of the samples and the
exclusion of patients with multiple comorbidities. However,
the association has been significant in real-world reports, as
observed in the present investigation and in previous
observational studies (risk ratio [RR] = 1.67; 95% CI 1.49 to
1.87) (28). It should also be emphasized that current use of
GCs was not a protective factor against allergic or immune-
mediated CAEs in the present study.
Benucci et al. found no significant differences among
TNF-a blockers in terms of the incidence of acute and late-
onset hypersensitivity (infused or local) during the first year
of treatment (29). In the present study, immune-mediated
reactions, especially types I and III hypersensitivity, were
more common than infectious CAEs, and interestingly, type
II reactions were infrequent (7).
Four CAEs were unexpected in the present cohort,
including two cases of immune-mediated reactions (psor-
iasis-like lesions and SLE) and two representative cases of
latent infection (lepromatous leprosy and herpes zoster).
Although TNF-a blockers have been widely used for the
treatment of psoriasis and PA in patients with inadequate
responses to conventional DMARDs (3,5), this treatment
Table 4 - Final logistic regression model of the significant
risk factors associated with CAEs in 257 patients with
chronic inflammatory arthritis taking TNF-a blockers.
OR (95% CI) p-value
Age { 1.09 (1.05-3.72) 0.03
Female sex 2.84 (1.90-5.63) ,0.001
RA 1.89 (1.11-4.62) 0.02
Disease activity index {{
DAS28 (n = 170) 1.52 (1.2-4.68) 0.03
BASDAI (n =91) 1.13 (1.02-6.37) 0.045
GCs 1.21 (1.09-8.15) 0.037
IFX 1.60 (1.06-4.01) 0.01
Final logistic regression model: RA: rheumatoid arthritis; DAS28: Disease
Activity Score-28; BASDAI: Bath Ankylosing Spondylitis Disease Activity
Index; GCs: glucocorticoid steroids; IFX: infliximab; CI: confidence interval;
{: for each additional year; {{: for each additional unit.
Table 5 - Strategies used regarding immunobiological
agents following adverse skin events.
Strategy – Discontinuation n
Temporary 34 (47.9%)
Definitive 37 (52.1%)
Replace with other anti-TNFa 33 (46.5%)
Replace with other non-TNFa blocker 4 (5.6%)
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might paradoxically also induce psoriasis-like lesions, even
among individuals with no personal or family history of
psoriasis, as observed in three patients in our sample. These
lesions are generally new, but some studies have reported a
worsening of preexisting lesions (psoriasis ‘‘de novo’’ or
psoriasis-like rash) (30), and such lesions are more common
in women, with a predilection for palm or plantar
involvement or in uncommon regions of the body, such as
the groin and pubic region, and they more commonly
emerge between 12 weeks and 12 months after the onset of
therapy (30-33). In the present study, serology was negative
for human immunodeficiency virus, and no sex differences
were found. Moreover, there was no evidence of palm or
plantar involvement, and all of the cases were associated
with IFX. Curiously, patients with inflammatory bowel
disease who received IFX did not appear to be at a greater
risk for CAEs, unlike those with CIA (15). Patients with JIA
were reported to experience greater difficulty in controlling
these lesions, even after the withdrawal of anti-TNF-a
therapy (34).
According to the British Society for Rheumatology
Biologics Registry (2001 to 2007), the incidence of psoriatic
lesions in a group of 9,826 RA patients taking TNF-a
inhibitors, especially those using ADA, was 1.04 per 1,000
patient-years (95% CI: 0.67 to 1.54), which is equivalent to 25
new cases of psoriasis. In contrast, no cases were found in
the group of 2,880 patients with RA treated with DMARDs
only (33).
The first hypothesis to explain this association would be
initial diagnostic error, as these lesions could actually be
part of the spondyloarthritis spectrum, and the association
with psoriasis could be nothing more than the natural
history of the disease (33). Subsequently, a modified Th1
response caused by TNF-a blockers and the direct role of
TNF-a itself were indicated as the most likely mechanisms,
as the inflammatory response in plaque psoriasis is
traditionally initiated by the activation of T cells (30,35).
Furthermore, the inhibition of TNF-a reduces the migration
of lymphocytes from the skin to the lymph nodes, and this
imbalance can promote a relative increase in IFN-c and
intensive activation of T cells, with a resulting increase in
psoriatic lesions (32). Other cytokine receptors have also
been cited in this process, such as CXCR3 (36). In addition,
IFN-a, IL-17 and IL-23 have recently been reported to
constitute another pathophysiological mechanism involved
in psoriasis-like processes (30,37). A number of authors also
believe that greater exposure to infectious agents, stemming
from heightened susceptibility following anti-TNF-a ther-
apy, represents another probable hypothesis (31,38); the
most commonly cited triggering microorganisms include
Gram-positive cocci (39) and, more recently, chlamydia (31).
TNF-a blockers are associated with the generation of
autoantibodies, including human anti-chimeric and anti-
human antibodies, as well as potentially clinically important
autoimmune involvement (39-41). The most prevalent
autoantibodies are generally directed against the nucleus
(AAN, anti-histone and anti-DNA), but antibodies are also
formed against membrane phospholipids (anticardiolipin)
(40,41). Clinically, these autoantibodies can induce SLE,
preferentially affecting the skin, joints and, less frequently,
the blood and kidneys (42-46).
No risk factors (previous positivity for autoantibodies,
age, prolonged GC use or administration of other medica-
tions traditionally related to drug-induced lupus) have yet
been identified as being associated with a greater chance of
stimulating lipopolysaccharide-induced TNF production.
Although a recent literature review indicated that IFX and
ETN represented the drugs most associated with lipopoly-
saccharide-induced TNF production (42), no recommenda-
tions have been reported for the study of autoantibodies in
patients with an indication for anti-TNF-a therapy. In one
patient in the present study, lipopolysaccharide-induced
TNF disappeared following the discontinuation of ETN and
initiation of GCs, and adequate clinical and laboratory
control of the disease was achieved with RTX.
Because TNF is important for the formation and main-
tenance of granulomas, TNF-a blockers can disorganize this
process, resulting in the reactivation of latent granuloma-
tous infections, such as tuberculosis and LL. According to
the Food and Drug Administration database, the incidence
of infection with Mycobacterium leprae is low (0.1%) and
more closely related to IFX therapy (47). In the present
sample, the Virchowian form of Hansen’s disease emerged
soon after the use of ADA, requiring prolonged specific
treatment and difficult management of the joint condition
(10).
Anti-TNF-a therapy could also be associated with the
reactivation of latent viral infections, such as herpes zoster,
which has traditionally been reported in patients with some
degree of immunosuppression. The incidence of viral
reactivation per 1,000 patient-years was shown to be
approximately two-fold greater (11.1; 95% CI: 7.9 to 15.1)
for patients treated with monoclonal antibodies, compared
to those treated with traditional DMARDs (5.6; 95% CI: 3.6
to 8.3), especially among older patients and among those
using concomitant GCs (12). After assessing the German
biologics registry database (RABBIT) and more than 5,000
RA patients administered biologic agents between 2001 and
2006, Strangefeld et al. identified 86 cases (16.3%) of
reactivation of shingles in 82 individuals; of these, 39 cases
were temporarily related to treatment with ADA or IFX, 23
were related to ETN, and 24 were related to traditional
DMARDs (11). Similarly, in a retrospective study,
McDonald et al. assessed more than 20,000 RA patients
from the Veterans Affairs Healthcare System (1998 to 2005),
and they found an incidence of 9.96 episodes/1,000 patient-
years. The main risk factors in this previous study were age,
prolonged GCs, cancer, chronic liver and lung disease,
immunosuppressants and kidney failure; ETN and ADA
exhibited a smaller risk than IFX (12).
Non-melanoma skin tumors constitute another commonly
reported skin manifestation among patients taking TNF-a
blockers, with a relative risk of 2.02, according to a recent
meta-analysis involving three TNF-a blockers (15). These
findings suggest that factors related to the immunopathol-
ogy of the skin, especially cells of the innate immune
system, such as dendritic cells, could play a crucial role in
the interrelationship of these events. However, further
prospective studies are needed to better establish this
association.
The present study demonstrated certain strengths that
should be highlighted, such as the long-term follow-up of
patients with CIA who were taking TNF-a inhibitors.
Moreover, the diagnostic accuracy of CAEs using gold-
standard methods, including dermatologic evaluation,
biopsies and cultures, should be noted. However, the lack
of a control group using DMARDs only was the main
limitation of this longitudinal cohort study.
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Rheumatologists and dermatologists should be aware of
the potential risks with TNF-a blockers, especially infectious
and immune-mediated adverse skin events, to establish an
early diagnosis and to make proper treatment decisions.
Furthermore, the adequate determination of epidemiologi-
cal and personal historical data (previous or recurrent
infectious conditions, subclinical fungal infections, oral
microbiota and oral health status) is fundamental to the
recognition and minimization of CAEs related to immuno-
biological therapy.
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